psoriasis cream psoriasis rare disease patients hospital
psoriasis treatment psoriasis vulgaris psoriasis pathology
LASEROPTEK declares the official launch of PALLAS Premium in the United States and embarks on capturing the local markets for vitiligo and psoriasis treatments.
LASEROPTEK announced that it will hold a large-scale launching event for PALLAS Premium in the United States at the American Academy of Dermatology (AAD 2024) conference in San Diego starting on the 8th.
LASEROPTEK PALLAS Premium is the world's first 311nm solid-state UV laser using titanium sapphire. The FDA has approved it for treating psoriasis, vitiligo, atopic dermatitis, and leukoderma.
At this launch event, Dr. Neil Shah from Clarus Dermatology, a global key doctor of LASEROPTEK, will present clinical cases secured from actual patients in the United States. Additionally, global key opinion leaders (KOLs) of LASEROPTEK, such as Dr. Victor Ross and Dr. Steven Shapiro, renowned experts in pigmentation therapy, will also attend in large numbers.
LASEROPTEK, particularly with this product launch, plans to significantly improve the accessibility of treatments for vitiligo and psoriasis by simplifying the complex medical billing and insurance reimbursement CPT (Current Procedural Terminology) coding through a strategic partnership with The Pinnacle Health Group in the United States.
The Pinnacle Health Group is a global healthcare consulting firm that provides consulting services on medical devices, pharmaceuticals, and insurance reimbursement.
It is mainly known for its expertise in consulting on reimbursement strategies for new technologies, products, and related therapies.
Furthermore, the sales strategy is being strengthened. The aesthetic and medical divisions are being operated separately to maximize operational efficiency.
The aesthetic division established a sales network across North America through an exclusive distribution agreement with Monarch Laser Services.
The medical division is operated by locally dedicated personnel and managed directly.
he services are also prepared to be available nationwide across North America through local specialized distributors.
Although it has not yet been officially launched, LASEROPTEK officials have reported significant local interest, to the extent that some pre-sales have been conducted upon requests from physicians interested in vitiligo and psoriasis treatments.
LASEROPTEK CEO Lee Chang-jin stated, 'LASEROPTEK has set new standards in the field of skin disease treatment with innovative laser technology. Through close collaboration with The Pinnacle Health Group, we will enhance accessibility for vitiligo and psoriasis patients in the United States to experience solid-state laser treatment more conveniently.'
According to the Global Vitiligo Foundation, an estimated 70 million vitiligo patients are worldwide. In the United States alone, 1-2% of the total population is estimated to suffer from vitiligo.
According to the National Psoriasis Foundation, as of the end of 2022, there were over 8 million psoriasis patients in the United States, with research indicating a prevalence rate of approximately 3%.
